title: CAR T-cell therapy for pancreatic cancer.
abstract: Chimeric antigen receptor (CAR) T-cell therapy utilizes genetic engineering to redirect a patient's own T cells to target cancer cells. The remarkable results in hematological malignancies prompted investigating this approach in solid tumors such as pancreatic cancer. The complex tumor microenvironment, stromal hindrance in limiting immune response, and expression of checkpoint blockade on T cells pose hurdles. Herein, we summarize the opportunities, challenges, and state of knowledge in targeting pancreatic cancer with CAR T-cell therapy.
authors.affiliation: Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, New York.
authors.forename: Carl J
authors.initials: CJ
authors.lastname: DeSelm
authors.affiliation: Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
authors.forename: Zachary E
authors.initials: ZE
authors.lastname: Tano
authors.affiliation: Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
authors.forename: Anna M
authors.initials: AM
authors.lastname: Varghese
authors.affiliation: Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, New York.|Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
authors.forename: Prasad S
authors.identifier: http://orcid.org/0000-0002-1699-2046
authors.initials: PS
authors.lastname: Adusumilli
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology; D051927:CD24 Antigen / Q000276:immunology; D002272:Carcinoembryonic Antigen / Q000276:immunology; D002986:Clinical Trials as Topic; D058851:GPI-Linked Proteins / Q000276:immunology; D006801:Humans; D016219:Immunotherapy, Adoptive; D000090204:Mesothelin; D018396:Mucin-1 / Q000276:immunology; D009363:Neoplasm Proteins / Q000276:immunology; D010190:Pancreatic Neoplasms / Q000276:immunology* / Q000628:therapy*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology; D011948:Receptors, Antigen, T-Cell; D055607:Receptors, Natural Killer Cell / Q000276:immunology; D017154:Stromal Cells / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology / Q000637:transplantation*; D019172:Transplantation Conditioning
chemical_list: D000951:Antigens, Neoplasm; D051927:CD24 Antigen; D002272:Carcinoembryonic Antigen; D058851:GPI-Linked Proteins; D000090204:Mesothelin; D018396:Mucin-1; D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011948:Receptors, Antigen, T-Cell; D055607:Receptors, Natural Killer Cell; C497889:CD24 protein, human; C060192:MUC1 protein, human; C110843:PSCA protein, human; C508053:ERBB2 protein, human
keywords: CAR T cells; adoptive cell therapy; checkpoint blockade; chimeric antigen receptor; immunotherapy